$MGNX
MACROGENICS INC

2023 Q3 Form 10-Q Financial Statement

#000112534523000108 Filed on August 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $10.40M $13.14M $26.01M
YoY Change -75.09% -49.49% -15.44%
Cost Of Revenue $85.00K $258.0K $180.0K
YoY Change -97.17% 43.33% 718.18%
Gross Profit $10.31M $12.88M $25.83M
YoY Change -73.37% -50.14% -15.97%
Gross Profit Margin 99.18% 98.04% 99.31%
Selling, General & Admin $12.40M $13.69M $13.67M
YoY Change -19.24% 0.17% -10.27%
% of Gross Profit 120.25% 106.32% 52.93%
Research & Development $30.13M $43.23M $51.74M
YoY Change -37.48% -16.46% -7.24%
% of Gross Profit 292.19% 335.68% 200.35%
Depreciation & Amortization $1.950M $2.812M $2.877M
YoY Change -31.43% -2.26% 3.49%
% of Gross Profit 18.91% 21.84% 11.14%
Operating Expenses $30.13M $43.23M $51.74M
YoY Change -37.48% -16.46% -7.24%
Operating Profit -$35.50M -$44.96M -$41.81M
YoY Change 42.26% 7.54% 3.8%
Interest Expense $0.00 $774.0K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $3.100M $2.275M $504.0K
YoY Change 2083.1% 351.39% 46.51%
Pretax Income $17.60M $57.47M -$41.30M
YoY Change -170.93% -239.14% 3.43%
Income Tax
% Of Pretax Income
Net Earnings $17.55M $57.47M -$41.30M
YoY Change -170.75% -239.14% 3.43%
Net Earnings / Revenue 168.84% 437.49% -158.82%
Basic Earnings Per Share $0.28 $0.93 -$0.67
Diluted Earnings Per Share $0.28 $0.92 -$0.67
COMMON SHARES
Basic Shares Outstanding 61.95M shares 61.84M shares 61.38M shares
Diluted Shares Outstanding 62.24M shares 62.26M shares 61.38M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $256.4M $240.3M $133.7M
YoY Change 107.42% 79.71% -55.02%
Cash & Equivalents $89.90M $108.8M $21.47M
Short-Term Investments $166.5M $131.6M $112.3M
Other Short-Term Assets $8.500M $6.475M $12.56M
YoY Change -8.34% -48.44% -30.06%
Inventory $1.066M $1.443M $2.949M
Prepaid Expenses
Receivables $25.31M $6.410M $18.39M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $291.3M $254.7M $167.6M
YoY Change 97.09% 51.92% -54.32%
LONG-TERM ASSETS
Property, Plant & Equipment $22.63M $24.09M $34.02M
YoY Change -29.25% -29.19% -13.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.387M $1.386M $16.39M
YoY Change -91.08% -91.54% -16.05%
Total Long-Term Assets $48.65M $50.98M $50.41M
YoY Change 2.35% 1.13% -14.44%
TOTAL ASSETS
Total Short-Term Assets $291.3M $254.7M $167.6M
Total Long-Term Assets $48.65M $50.98M $50.41M
Total Assets $340.0M $305.7M $218.0M
YoY Change 74.03% 40.18% -48.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.303M $3.795M $2.609M
YoY Change -28.49% 45.46% -73.43%
Accrued Expenses $25.48M $27.53M $31.76M
YoY Change -23.54% -13.33% -18.92%
Deferred Revenue $18.58M $9.671M $11.57M
YoY Change 162.3% -16.38% -30.18%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $51.29M $45.16M $50.88M
YoY Change 2.49% -11.25% -27.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $258.0K $258.0K $258.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Liabilities $258.0K $258.0K $258.0K
YoY Change 0.0% 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $51.29M $45.16M $50.88M
Total Long-Term Liabilities $258.0K $258.0K $258.0K
Total Liabilities $146.0M $134.1M $75.56M
YoY Change 101.68% 77.48% -29.29%
SHAREHOLDERS EQUITY
Retained Earnings -$1.057B -$1.074B -$1.082B
YoY Change -4.5% -0.69% 25.34%
Common Stock $1.251B $1.246B $1.224B
YoY Change 1.72% 1.74% 3.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $194.0M $171.5M $142.5M
YoY Change
Total Liabilities & Shareholders Equity $340.0M $305.7M $218.0M
YoY Change 74.03% 40.18% -48.81%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income $17.55M $57.47M -$41.30M
YoY Change -170.75% -239.14% 3.43%
Depreciation, Depletion And Amortization $1.950M $2.812M $2.877M
YoY Change -31.43% -2.26% 3.49%
Cash From Operating Activities -$35.25M -$2.089M -$49.16M
YoY Change 274.12% -95.75% 7.61%
INVESTING ACTIVITIES
Capital Expenditures $490.0K $286.0K -$1.011M
YoY Change -160.95% -128.29% -50.99%
Acquisitions
YoY Change
Other Investing Activities -$33.02M -$113.2M $24.05M
YoY Change -145.39% -570.64% 51.41%
Cash From Investing Activities -$33.53M -$113.5M $23.04M
YoY Change -146.6% -592.54% 66.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 49.91M 59.00K 263.0K
YoY Change -77.57% -88.78%
NET CHANGE
Cash From Operating Activities -35.25M -2.089M -49.16M
Cash From Investing Activities -33.53M -113.5M 23.04M
Cash From Financing Activities 49.91M 59.00K 263.0K
Net Change In Cash -18.87M -115.5M -25.86M
YoY Change -130.18% 346.68% -12.4%
FREE CASH FLOW
Cash From Operating Activities -$35.25M -$2.089M -$49.16M
Capital Expenditures $490.0K $286.0K -$1.011M
Free Cash Flow -$35.74M -$2.375M -$48.15M
YoY Change 314.71% -95.07% 10.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
202720 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
21.58
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
239618000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5224000 usd
CY2022Q1 mgnx Stock Issued During Period Value Stock Plan Activity
StockIssuedDuringPeriodValueStockPlanActivity
37000 usd
CY2022Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-222000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-66443000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
178214000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5350000 usd
CY2022Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
264000 usd
CY2022Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-43000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-41304000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
142481000 usd
us-gaap Net Income Loss
NetIncomeLoss
19460000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5795000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1404000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
9224000 usd
mgnx Gain On Royalty Monetization Arrangement
GainOnRoyaltyMonetizationArrangement
100930000 usd
mgnx Non Cash Interest Expense Recognized
NonCashInterestExpenseRecognized
1430000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-236000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1077000 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3686000 usd
mgnx Operating Lease Noncash Expense
OperatingLeaseNoncashExpense
1834000 usd
mgnx Operating Lease Noncash Expense
OperatingLeaseNoncashExpense
1622000 usd
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-12896000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1697000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2264000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2918000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-106857000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
75457000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
82440000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2426000 usd
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4557000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
mgnx Proceedsfrom Stock Options Exercised And Espp Purchases
ProceedsfromStockOptionsExercisedAndESPPPurchases
300000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 usd
mgnx Principal Payments On Royalty Monetization Arrangement
PrincipalPaymentsOnRoyaltyMonetizationArrangement
0 usd
mgnx Net Proceeds From Sale Of Future Royalties
NetProceedsFromSaleOfFutureRoyalties
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
300000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-102000000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21469000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
295000 usd
CY2022Q4 mgnx Liability Related To Future Royalties
LiabilityRelatedToFutureRoyalties
0 usd
mgnx Proceeds From Sale Of Future Royalties
ProceedsFromSaleOfFutureRoyalties
100000000 usd
mgnx Deferred Transaction Costs
DeferredTransactionCosts
344000 usd
mgnx Principal Payments On Royalty Monetization Arrangement
PrincipalPaymentsOnRoyaltyMonetizationArrangement
156000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
131661000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
16000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
88000 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
131589000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
45467000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
45462000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
221000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
409000 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1222000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1042000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
1443000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
1451000 usd
CY2023Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
4900000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
4900000 usd
mgnx Gain On Royalty Monetization Arrangement
GainOnRoyaltyMonetizationArrangement
100900000 usd
mgnx Non Cash Interest Expense Recognized
NonCashInterestExpenseRecognized
1430000 usd
mgnx Gain On Royalty Monetization Arrangement
GainOnRoyaltyMonetizationArrangement
100930000 usd
CY2023Q2 mgnx Liability Related To Future Royalties
LiabilityRelatedToFutureRoyalties
0 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q2 mgnx Share Based Compensation Arrangement By Share Based Payment Award Offering Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
P6M
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4391000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5300000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9224000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10574000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M17D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10098929 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.58
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3177827 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.91
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
14990 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.37
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
198435 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12860611 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.30
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2093000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7295883 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
20.48
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M18D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
342000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11839534 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
15.81
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1819000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.78
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
500000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
300000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3500000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
9400000 usd
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
26200000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12561277 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12236505 shares
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
57469000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-41304000 usd
us-gaap Net Income Loss
NetIncomeLoss
19460000 usd
us-gaap Net Income Loss
NetIncomeLoss
-107747000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61880096 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61384943 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61845151 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61354721 shares
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
381550 shares
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
185559 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62261646 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61384943 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62030710 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61354721 shares
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.93
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.76
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.92
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.76

Files In Submission

Name View Source Status
0001125345-23-000108-index-headers.html Edgar Link pending
0001125345-23-000108-index.html Edgar Link pending
0001125345-23-000108.txt Edgar Link pending
0001125345-23-000108-xbrl.zip Edgar Link pending
exhibit31-1q22023.htm Edgar Link pending
exhibit31-2q22023.htm Edgar Link pending
exhibit32-1q22023.htm Edgar Link pending
exhibit32-2q22023.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mgnx-20230630.htm Edgar Link pending
mgnx-20230630.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mgnx-20230630_cal.xml Edgar Link unprocessable
mgnx-20230630_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
mgnx-20230630_pre.xml Edgar Link unprocessable
mgnx-20230630_def.xml Edgar Link unprocessable
mgnx-20230630_lab.xml Edgar Link unprocessable